Andrew Leuchter

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project
    Andrew F Leuchter
    Department of Psychiatry and Biobehavioral Sciences, and the Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA UCLA Depression Research and Clinic Program, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA Electronic address
    J Psychiatr Res 54:11-8. 2014
  2. pmc The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder
    Andrew F Leuchter
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles Los Angeles, CA, USA
    Front Hum Neurosci 7:37. 2013
  3. pmc Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression
    Andrew F Leuchter
    Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 7:e32508. 2012
  4. ncbi request reprint Changes in brain function of depressed subjects during treatment with placebo
    Andrew F Leuchter
    UCLA Neuropsychiatric Institute, Los Angeles, CA 90024 1759, USA
    Am J Psychiatry 159:122-9. 2002
  5. ncbi request reprint Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report
    A F Leuchter
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
    Psychol Med 40:239-51. 2010
  6. ncbi request reprint Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence
    Andrew F Leuchter
    Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
    Clin EEG Neurosci 40:78-83. 2009
  7. ncbi request reprint Changes in brain function during administration of venlafaxine or placebo to normal subjects
    Andrew F Leuchter
    Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
    Clin EEG Neurosci 39:175-81. 2008
  8. doi request reprint Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder
    Andrew F Leuchter
    Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
    Psychiatry Res 169:132-8. 2009
  9. doi request reprint Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study
    Andrew F Leuchter
    Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
    Psychiatry Res 169:124-31. 2009
  10. pmc An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder
    Andrew F Leuchter
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
    J Psychiatr Pract 14:271-80. 2008

Research Grants

  1. ENHANCING TREATMENT OUTCOMES IN DEPRESSION
    Andrew Leuchter; Fiscal Year: 2004
  2. Psychobiologic Factors of the Placebo Response in MDD
    Andrew Leuchter; Fiscal Year: 2004
  3. Psychobiologic Factors of the Placebo Response in MDD
    Andrew Leuchter; Fiscal Year: 2006
  4. Psychobiologic Factors of the Placebo Response in MDD
    Andrew Leuchter; Fiscal Year: 2007
  5. RESEARCH TRAINING: PSYCHOBIOLOGICAL SCIENCES
    Andrew Leuchter; Fiscal Year: 2007
  6. Psychobiologic Factors of the Placebo Response in MDD
    Andrew Leuchter; Fiscal Year: 2005

Detail Information

Publications42

  1. ncbi request reprint Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project
    Andrew F Leuchter
    Department of Psychiatry and Biobehavioral Sciences, and the Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA UCLA Depression Research and Clinic Program, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA Electronic address
    J Psychiatr Res 54:11-8. 2014
    ..Measuring theta cordance after one week of treatment could be useful in predicting atomoxetine treatment response in adult ADHD. ..
  2. pmc The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder
    Andrew F Leuchter
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles Los Angeles, CA, USA
    Front Hum Neurosci 7:37. 2013
    ..We present here the theory and evidence indicating that these modifications could enhance the therapeutic effectiveness of rTMS for the treatment of MDD...
  3. pmc Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression
    Andrew F Leuchter
    Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 7:e32508. 2012
    ..These results can inform the development of qEEG state and trait biomarkers for MDD...
  4. ncbi request reprint Changes in brain function of depressed subjects during treatment with placebo
    Andrew F Leuchter
    UCLA Neuropsychiatric Institute, Los Angeles, CA 90024 1759, USA
    Am J Psychiatry 159:122-9. 2002
    ..Both QEEG power and cordance, a new measure that reflects cerebral perfusion and is sensitive to the effect of antidepressant medication, were examined...
  5. ncbi request reprint Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report
    A F Leuchter
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
    Psychol Med 40:239-51. 2010
    ..Whether PPS significantly contribute to poorer treatment outcome overall in primary or specialty psychiatric care settings remains unclear...
  6. ncbi request reprint Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence
    Andrew F Leuchter
    Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
    Clin EEG Neurosci 40:78-83. 2009
    ..The current state of evidence supporting the use of each technique is reviewed...
  7. ncbi request reprint Changes in brain function during administration of venlafaxine or placebo to normal subjects
    Andrew F Leuchter
    Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
    Clin EEG Neurosci 39:175-81. 2008
    ..Future studies should examine other classes of medication, as well as antidepressants with other mechanisms of action, to determine if cordance detects antidepressant medication effects in general in normal subjects...
  8. doi request reprint Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder
    Andrew F Leuchter
    Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
    Psychiatry Res 169:132-8. 2009
    ..28%). The ATR index did not provide a useful prediction of response to combination treatment. The ATR index may prove useful in predicting responsiveness to different antidepressant medications...
  9. doi request reprint Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study
    Andrew F Leuchter
    Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
    Psychiatry Res 169:124-31. 2009
    ..Logistic regression showed that the ATR and early Ham-D(17) changes were additive predictors of response, but the ATR was the only significant predictor of remission. Future studies should replicate these results prior to clinical use...
  10. pmc An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder
    Andrew F Leuchter
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
    J Psychiatr Pract 14:271-80. 2008
    ..This pilot study was conducted to evaluate this combination in the treatment of MDD in patients with chronic or recurrent MDD to estimate safety, tolerability, and remission rates...
  11. pmc Biomarkers to predict antidepressant response
    Andrew F Leuchter
    Semel Institute for Neuroscience and Human Behavior at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
    Curr Psychiatry Rep 12:553-62. 2010
    ..Once such biomarkers are validated, they could form the basis of new paradigms for antidepressant treatment selection...
  12. pmc A new paradigm for the prediction of antidepressant treatment response
    Andrew F Leuchter
    Laboratory of Brain Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024, USA
    Dialogues Clin Neurosci 11:435-46. 2009
    ..We posit that this new paradigm could lead to earlier recovery from depressive illness and ultimately produce profound health and economic benefits...
  13. doi request reprint Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder
    Andrew F Leuchter
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, Rm 37 452, Los Angeles, CA 90024 1759, USA
    J Clin Psychopharmacol 29:372-7. 2009
    ..These findings support the hypothesis that genetic polymorphisms modulating monoaminergic tone are related to degree of placebo responsiveness in major depressive disorder...
  14. ncbi request reprint Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression
    Andrew F Leuchter
    UCLA NPI, 760 Westwood Plaza, Suite 37 452, Los Angeles, CA 90024 1759, USA
    Psychopharmacology (Berl) 177:15-22. 2004
    ..High placebo response rates are a confound in treatment trials for major depressive disorder (MDD). A method for prospective identification of placebo responders could enhance the efficiency of clinical trials...
  15. ncbi request reprint Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study
    Aimee M Hunter
    Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles, CA, USA
    Pain Med 10:730-8. 2009
    ..We hypothesized that cordance might also predict response to antidepressant medications for symptoms of FMS...
  16. ncbi request reprint Predictors of improved mood over time in clinical trials for major depression
    Ariane Marie-Mitchell
    Department of Preventive Medicine, University of Southern California Keck School of Medicine, 1540 Alcazar St, CHP 218, Los Angeles, CA 90033 9010, USA
    Psychiatry Res 127:73-84. 2004
    ..We recommend the use of repeated measures modeling, and the exploration of relationships among biological and psychological factors, for future analyses of clinical trial data...
  17. ncbi request reprint Influence of age, gender, health status, and depression on quantitative EEG
    Melinda L Morgan
    Behavioral Pharmacology Laboratory, UCLA Neuropsychiatric Institute, USA
    Neuropsychobiology 52:71-6. 2005
    ..Global measures of power, and to a lesser extent prefrontal absolute power, must be interpreted with regard to confounding factors of age, gender, physical illness, and severity of depression...
  18. ncbi request reprint Amygdala lateralization at rest and during viewing of neutral faces in major depressive disorder using low-resolution brain electromagnetic tomography
    Haleh Farahbod
    Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
    Clin EEG Neurosci 41:19-23. 2010
    ..Findings suggest a more pronounced lateralization effect in normal healthy controls than in MDD subjects when changing from a resting (eyes-closed) condition to viewing faces without emotional valence...
  19. ncbi request reprint Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition
    Sandy Venneman
    Medication Development Unit, Research Service, and Psychiatry Service, West Los Angeles VA Medical Center, California, USA
    J Neuropsychiatry Clin Neurosci 18:208-16. 2006
    ..Failure to complete the trial was not explained by depression, craving, benzoylecgonine levels or quantitative electroencephalogram (QEEG) power; thus cordance may help identify attrition risk...
  20. ncbi request reprint Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain
    Heather V Krell
    Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, 37 452 NPI, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    Psychosomatics 46:379-84. 2005
    ..Our experience with reboxetine suggests that this noradrenergic antidepressant may have efficacy in the treatment of chronic pain in patients with depression...
  21. doi request reprint Brain electrical source differences between depressed subjects and healthy controls
    Alexander S Korb
    Laboratory of Brain, Behavior, and Pharmacology, Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
    Brain Topogr 21:138-46. 2008
    ..Inconsistent findings among LORETA studies, and between LORETA studies and those using other functional imaging techniques, may result from differences in electrode montages...
  22. pmc Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression
    Alexander S Korb
    Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
    Clin Neurophysiol 120:1313-9. 2009
    ....
  23. pmc Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder
    Aimee M Hunter
    Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, United States
    J Psychiatr Res 44:90-8. 2010
    ..Statistical methods such as GMM are needed to identify clinically relevant symptom response trajectories...
  24. pmc Midline and right frontal brain function as a physiologic biomarker of remission in major depression
    Ian A Cook
    UCLA Depression Research and Clinic Program, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, United States
    Psychiatry Res 174:152-7. 2009
    ..These results suggest that remission may be predictable from physiologic measurements after 1 week of treatment, and that this region merits further investigation in the neurobiology of treatment response...
  25. ncbi request reprint Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, UCLA School of Medicine, Room A7 372, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    Clin Neurophysiol 115:194-8. 2004
    ..Exposure to methamphetamine is associated with long-lasting reductions in markers for dopaminergic neurons in preclinical models and in humans. These changes may be associated with alterations in brain electrical activity and in cognition...
  26. ncbi request reprint Insured and non-insured depressed outpatients: how do they compare?
    Ira M Lesser
    Department of Psychiatry, Harbor UCLA Medical Center, The Los Angeles Biomedical Research Institute, Los Angeles, CA, USA
    Ann Clin Psychiatry 19:73-82. 2007
    ....
  27. ncbi request reprint Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: a pilot study
    Ian A Cook
    UCLA Neuropsychiatric Institute and the Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine Los Angeles, CA 90024 1759, USA
    Int J Geriatr Psychiatry 17:610-8. 2002
    ..Cortical atrophy, central atrophy, deep white-matter hyperintensities, and periventricular hyperintensities are reported in normal aging...
  28. ncbi request reprint Cognitive and physiologic correlates of subclinical structural brain disease in elderly healthy control subjects
    Ian A Cook
    University of California, Los Angeles, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024 1759, USA
    Arch Neurol 59:1612-20. 2002
    ..Healthy elderly persons commonly show 4 types of change in brain structure-cortical atrophy, central atrophy, deep white-matter hyperintensities, and periventricular hyperintensities-as forms of subclinical structural brain disease (SSBD)...
  29. ncbi request reprint Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
    Clin Neurophysiol 114:410-5. 2003
    ....
  30. ncbi request reprint Longitudinal progression of subclinical structural brain disease in normal aging
    Ian A Cook
    UCLA Neuropsychiatric Institute and the Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA 90024 1759, USA
    Am J Geriatr Psychiatry 12:190-200. 2004
    ..Greater volumes were also associated with poorer cognition, even though subjects performed within the normal range. The natural history of these forms of SSBD and their functional impact are not well established...
  31. ncbi request reprint Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant
    Heather V Krell
    Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
    J Clin Psychiatry 65:1174-9. 2004
    ..To evaluate the association between treatment expectations and response in a 9-week, single-blind experimental antidepressant treatment study...
  32. ncbi request reprint Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo
    Aimee M Hunter
    Behavioral Pharmacology Laboratory, Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, David Geffen School of Medicine, Los Angeles, CA 90024 1759, USA
    Neuropsychopharmacology 30:792-9. 2005
    ..Results of these exploratory hypothesis-generating analyses should be considered tentative until replicated...
  33. ncbi request reprint Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study
    Melinda L Morgan
    Laboratory of Behavioral Pharmacology, University of California Los Angeles Neuropsychiatric Institute and Hospital, Department of Psychiatry and Biobehavioral Sciences, 90024, USA
    J Clin Psychiatry 66:774-80. 2005
    ..To investigate the effects of estrogen augmentation on mood and memory in women with perimenopausal depression who had experienced a partial response to antidepressant medications...
  34. ncbi request reprint Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study
    Ian A Cook
    Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, 760 Westwood Plaza, 37 451, Los Angeles, CA 90024 1759, USA
    J Psychiatr Res 39:461-6. 2005
    ..These findings suggest that cordance biomarkers may be a useful tool in effectiveness trials that parallel clinical practices in SSRI nonresponders, and may not require a wash-out period between treatments...
  35. ncbi request reprint Neurophysiologic changes during estrogen augmentation in perimenopausal depression
    Melinda L Morgan
    Laboratory of Brain, Behavior, and Pharmacology, Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, 760 Westwood Plaza, Suite 37 439, Los Angeles, CA 90024 1759, United States
    Maturitas 56:54-60. 2007
    ..We also assessed whether such changes were correlated with serum hormone levels...
  36. ncbi request reprint Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression
    Aimee M Hunter
    Semel Institute for Neuroscience and Human Behavior at UCLA, 760 Westwood Plaza, Rm 37 359, Los Angeles, CA 90024 1759, USA
    Am J Psychiatry 163:1426-32. 2006
    ..The authors hypothesized that decreases in prefrontal cordance during the placebo lead-in phase would be associated with better clinical outcome in subjects treated with antidepressants...
  37. ncbi request reprint Aging and brain activation with working memory tasks: an fMRI study of connectivity
    Ian A Cook
    UCLA Semel Institute for Neuroscience and Human Behavior, California 90024 1759, USA
    Int J Geriatr Psychiatry 22:332-42. 2007
    ..We hypothesized healthy older subjects would show lower connectivity than younger subjects...
  38. ncbi request reprint The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder
    Aimee M Hunter
    Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
    Psychiatr Clin North Am 30:105-24. 2007
    ....
  39. ncbi request reprint Early changes in prefrontal activity characterize clinical responders to antidepressants
    Ian A Cook
    Quantitative EEG Laboratory, Neuropsychiatric Institute and Hospital, UCLA School of Medicine, University of California, 760 Westwood Plaza, Los Angeles, CA 90024 1759, USA
    Neuropsychopharmacology 27:120-31. 2002
    ..These findings implicate the prefrontal region in mediating response to antidepressant medications. Cordance may have clinical applicability as a leading indicator of individual response...
  40. ncbi request reprint Pretreatment neurophysiologic function and ECT response in depression
    William F Stubbeman
    Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
    J ECT 20:142-4. 2004
    ..The present study tested the hypothesis that brain activity in midline apical quantitative EEG (QEEG) electrodes would be associated with therapeutic response to electroconvulsive therapy (ECT)...
  41. ncbi request reprint Does the clinical course of depression determine improvement in symptoms and quality of life?
    Tally Moses
    School of Social Work, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Nerv Ment Dis 194:241-8. 2006
    ..Our results support the trend of distinguishing between treatment-related change in QOL and symptomatic change and suggest clinical course factors as promising predictors of QOL...
  42. ncbi request reprint Characteristics of insured and noninsured outpatients with depression in STAR(*)D
    Ira M Lesser
    Harbor UCLA Medical Center, Box 8, 1000 West Carson Street, Torrance, California 90509, USA
    Psychiatr Serv 56:995-1004. 2005
    ....

Research Grants7

  1. ENHANCING TREATMENT OUTCOMES IN DEPRESSION
    Andrew Leuchter; Fiscal Year: 2004
    In this competing renewal application for a K02 award, Dr. Andrew Leuchter proposes a line of research and career enhancement aimed at improving outcomes of treatment for depression...
  2. Psychobiologic Factors of the Placebo Response in MDD
    Andrew Leuchter; Fiscal Year: 2004
    ..The results of this project will lead to better understanding of the mechanisms of the placebo response in MDD. ..
  3. Psychobiologic Factors of the Placebo Response in MDD
    Andrew Leuchter; Fiscal Year: 2006
    ..The results of this project will lead to better understanding of the mechanisms of the placebo response in MDD. ..
  4. Psychobiologic Factors of the Placebo Response in MDD
    Andrew Leuchter; Fiscal Year: 2007
    ..The results of this project will lead to better understanding of the mechanisms of the placebo response in MDD. ..
  5. RESEARCH TRAINING: PSYCHOBIOLOGICAL SCIENCES
    Andrew Leuchter; Fiscal Year: 2007
    ..The University is providing financial support for this predoctoral training program. These changes should lead to an enhanced training experience for a more diverse group of postdoctoral and predoctoral trainees. ..
  6. Psychobiologic Factors of the Placebo Response in MDD
    Andrew Leuchter; Fiscal Year: 2005
    ..The results of this project will lead to better understanding of the mechanisms of the placebo response in MDD. ..